Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance

• Published in: Diagnostic pathology Vol. 18; no. 1; pp. 1 - 125
• Main Authors: Elkady, Noha, Aldesoky, Amira I, Dawoud, Marwa Mohammed
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 23.11.2023; BioMed Central; BMC
• Subjects: Apoptosis; ARK5; Breast cancer; Cancer; Cancer therapies; Carcinoma, Renal cell; Chemotherapy; Chronic kidney failure; Correlation; End-stage renal disease; Hypoxia; Immunohistochemistry; Kidney cancer; Kidney diseases; Kinases; Medical prognosis; Metastasis; Microenvironments; Mitochondria; Polyclonal antibodies; Prognosis; Protein kinases; Proteins; RCC; Renal cell carcinoma; Response to therapy; SIRT3; Survival; Survival analysis; Therapy; Tumors; United States > US
• ISSN: 1746-1596; 1746-1596
• DOI: 10.1186/s13000-023-01409-6

Abstract Background Globally Renal Cell Carcinoma (RCC) represents 3% of malignant tumours in adults and 1.78% in Egypt. AMPK-related protein kinase 5 (ARK5) is mainly associated with a hypoxic microenvironment which is a feature of the major RCC subtypes. Additionally, it displays decreased mitochondrial respiration. SIRT3 is a mitochondrial deacetylase that modifies multiple mitochondrial proteins. Material and methods Fifty eight cases of RCC, and 30 non-neoplastic cases (of End-Stage Kidney Disease (ESKD) were subjected to immunohistochemistry by ARK5 and SIRT3. The results of IHC were correlated together and correlated with the available clinicopathologic and survival data. Results Although no significant difference was detected between RCC and ESKD groups regarding ARK5 expression, there was a significant association with RCC regarding H-score and nucleocytoplasmic expression (both P  = 0.001). Also, SIRT3 was highly expressed in RCC in comparison to the ESKD group (H-score: P  = 0.001). There were significant associations between nucleocytoplasmic ARK5 expression and higher tumour grade, low apoptotic and high mitotic indices, tumour extent, advanced tumour stage, and impaired response of tumours to chemotherapeutic drugs ( P  = 0.039, P  = 0.001, P  = 0.027, P  = 0.011, P  = 0.009, and P  = 0.014 respectively). Moreover, the H score of ARK5 expression showed significant associations with tumour grade, apoptotic and mitotic indices, tumour extension, tumour stage, and response to therapy ( P  = 0.01, 0.035, 0.001, 0.004. 0.003 and 0.013). Regarding SIRT3 expression, it showed significant associations with apoptotic and mitotic indices, tumour extent, tumour stage and response to therapy ( P  = 0.022, 0.02, 0.042, 0.039 and 0.027). Interestingly, there was a highly significant correlation between the expression of ARK5 and SIRT3 ( P  = 0.009). Univariate survival analysis revealed a significant association between short survival duration and both nucleocytoplasmic expression of ARK5 and positive SIRT3 expression ( P  = 0.014 and 0.035). Conclusion ARK5 and SIRT3 are overexpressed in RCC and associated with parameters of poor prognosis as well as short survival. Both seem to influence response to therapy in RCC. So, they could be new targets for therapy that may improve tumour response and patients’ survival. There is a postulated relationship that needs more extensive investigation.